Background: It has not yet been determined whether hepatic arterial infusion (HAI) chemotherapy improves survival in patients with early hepatocellular carcinoma (HCC). We evaluated the effectiveness of HAI with high-concentration cisplatin (DDP-H) for the treatment of HCC by comparing outcomes between patients who received HAI with DDP-H before radical local treatment of early-stage HCC [Japan Integrated Staging (JIS) score 0/1] and patients who did not receive HAI chemotherapy.
introduction
Recent technological advances in diagnostic imaging and therapeutic devices have remarkably improved outcomes after the radical local treatment of early hepatocellular carcinoma (HCC). However, HCC frequently recurs after radical local treatment, and may progress to uncontrollable advanced disease. It is preferable to develop treatment options that are less invasive than radical local treatment and maintain residual liver function. As there is a high risk of recurrence in the residual liver, therapeutic strategies to prevent recurrence should be established before treatment is initiated. Intrahepatic recurrence is categorized as multicentric carcinogenesis or distant metastasis, but it is not easy to differentiate between these types of recurrence. Based on tumor growth patterns, recurrence within 2 years of radical treatment is considered to be distant metastasis, and recurrence after 3 years is considered to be multicentric carcinogenesis [1] . HCC generally has low sensitivity to anticancer chemotherapy, and the role of systemic administration of anticancer agents is unclear [2] . Previous trials reported that preoperative transcatheter arterial embolization (TAE) and transcatheter arterial chemoembolization (TACE) were not associated with improved survival [3] [4] [5] [6] . The effectiveness of adjuvant chemotherapy has also not been established, and outcomes after hepatic arterial infusion (HAI) with a high concentration of a fine-powder formulation of cisplatin (DDP-H) (IA-call®; Nippon Kayaku Co. Ltd, Tokyo, Japan) have not been well evaluated. However, effective preoperative chemotherapy protocols for the treatment of intrahepatic micrometastases may prevent recurrence and improve survival.
As HAI can deliver a high drug concentration to a specific site, it is expected that administration of HAI chemotherapy can improve the prognosis of HCC patients. We previously reported that HAI with DDP-H can reduce intrahepatic distant micrometastases [7, 8] . However, it is unclear whether reduction of intrahepatic distant micrometastases prolongs survival. It is very important to maintain residual liver function to prolong survival in HCC patients.
Many prognostic staging systems to evaluate HCC severity have been established, but it is still unclear which system is the most useful. In Japan, patients with viral hepatitis who are at high risk for HCC undergo periodic screening, enabling diagnosis of HCC in the early stage. The Japan Integrated Staging (JIS) score is commonly used to evaluate HCC severity in Japan, because this score reflects both the TNM stage and the ChildPugh score [9] .
The aim of the current study was to evaluate whether HAI with DDP-H before local radical treatment improves survival in patients with early-stage primary HCC (JIS 0/1).
patients and methods patients
This was a single-center, prospective cohort study of patients with earlystage primary HCC diagnosed between September 2002 and November 2011. The survival time and predictive factors for survival were analyzed in 114 patients who received radical local treatment with TACE and radiofrequency ablation (RFA) or percutaneous ethanol injection therapy (PEI), followed by nonsurgical treatment only. Seventy-nine patients received HAI with DDP-H before radical local treatment (HAI group), and the remaining 35 patients did not receive HAI chemotherapy before radical local treatment (non-HAI group). The inclusion criteria were JIS score 0/1, no prior treatment of HCC, poor candidate for surgery, performance status (ECOG) 0−2, normal electrocardiographic findings, normal serum creatinine level, and age 20-85 years.
The study protocol was approved by our institutional review board, and all patients provided written informed consent.
treatment
In the non-HAI group, a catheter was advanced into a tumor-feeding artery according to the Seldinger technique. An anticancer drug mixed with lipiodol emulsion was infused through the catheter until stasis of the blood flow in the target artery was observed. The treatment dose was determined by the tumor diameter. Embolization was then carried out with gelatin sponge particles. If further radical local therapy is feasible (depending on the location of the tumor), patients also received RFA or PEI. Postoperative computed tomography was carried out to ensure absence of residual lesions.
In the HAI group, a catheter was advanced into the proper hepatic artery, and DDP-H 65 mg/m 2 was infused through the catheter into the whole liver over 30 min. The DDP-H solution was prepared by dissolving DDP-H (100 mg/vial) in 70 ml of physiological saline warmed to 50°C (cisplatin concentration: 1.43 mg/ml). A 5-hydroxytryptamine-3 receptor antagonist and corticosteroid were administered during DDP-H infusion to reduce emesis. After DDP-H infusion, TACE was carried out as described above. To prevent renal toxicity, i.v. fluids were administered (500 ml before cisplatin infusion and 1500 ml after cisplatin infusion) and patients were instructed to drink >2000 ml of water the day after treatment.
statistical analysis
The primary end point of this study was overall survival. Background clinical characteristics were compared between the non-HAI and HAI groups by the Wilcoxon rank sum test or Fisher's exact test. Overall survival was calculated from the date of initiation of therapy to the date of death, and survival curves were constructed by the Kaplan-Meier method. Overall survival was compared between the two groups by the log-rank test and generalized Wilcoxon test. Prognostic factors were identified by univariate and multivariate analyses using the Cox proportional hazards model. Values of P < 0.05 were considered to be statistically significant. All analyses were carried out using Statistical Analysis System software (version 9.2; SAS Institute, Inc., Cary, NC). Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria, version 4.0.
results patient characteristics
There were no significant differences in background clinical characteristics between the non-HAI and HAI groups ( Table 1) . The median follow-up period for all 114 patients was 36.8 months (range 4.3−108.6 months).
overall survival
The cumulative 1-, 3-, and 5-year survival rates were 77.4%, 69.2%, and 55.3% in the non-HAI group, and 97.4%, 87.0%, and 84.4% in the HAI group, respectively. This was a significant difference between the two groups (log-rank test, P = 0.023; generalized Wilcoxon test, P = 0.012; Figure 1 (Table 3) . Therefore, preceding HAI was considered to be the most important factor affecting survival.
adverse events
Grade 3 or 4 adverse events occurred in both the non-HAI and HAI groups (Table 4 ). In the non-HAI group, these events included an elevated aspartate aminotransferase (AST) level in nine patients (25.7%), elevated alanine aminotransferase (ALT) level in six (17.1%), thrombocytopenia in four (11.4%), hyperbilirubinemia in one (2.9%), and hypoalbuminemia in one (2.9%).
In the HAI group, these events included elevated AST level in 47 patients (59.5%), elevated ALT level in 24 (30.4%), thrombocytopenia in 15 (19.0%), hyperbilirubinemia in 1 (1.3%), and hypoalbuminemia in 1 (1.3%). The grade 3 or 4 elevation in AST level was transient in all patients, and there was no significant difference in the time to return of the AST level to normal between the two groups.
Group of Japan reported that the initial diagnosis was single HCC in 57.9% of the 15 788 patients included [10] . However, the study group was concerned about the high rate of recurrence after treatment. Even when HCC is treated radically by hepatectomy or RFA and is well controlled locally, distant recurrence is common [11] [12] [13] . In spite of repeated therapy for recurrent lesions, HCC often progresses to an uncontrollable advanced stage, with features such as multiple tumors and vascular invasion. A microsatellite nodule that exists at the time of primary therapy may cause distant recurrence. Sasaki et al. [14] retrospectively found microsatellite lesions in 46 of 100 small (≤5 cm) liver cancer specimens after hepatectomy. The high rate of recurrence is a major obstacle to improving prognosis. Imamura et al. [11] proposed that early recurrence (within 2 years) is mainly caused by intrahepatic metastasis of the primary HCC, whereas late recurrence is mainly caused by de novo tumors resulting from the 'field effect' in the diseased liver, which has similar viral loads and hepatic inflammatory activity to the area of the primary HCC. To prevent intrahepatic metastasis, patients should undergo treatment such as HAI to ensure that both overt lesions and micrometastases are eliminated [1] . In Japan, DDP-H has been available for intra-arterial infusion for the treatment of HCC since 2004. DDP-H can easily be dissolved in saline solution at a high concentration, giving a cisplatin concentration of 1.43 mg/ml. A phase II study of DDP-H treatment of unresectable advanced HCC reported a response rate of 33.8% and a 1-year survival rate of 67.5% [15] . A clinical trial of TACE with DDP-H and gelatin sponge (Gelpart; Nipponkayaku Co. Ltd, Tokyo, Japan) for unresectable bilobar multifocal HCC reported a response rate of 64.1% and a 1-year survival rate of 75.3% [16] . These results show the high efficacy [17] retrospectively compared cisplatin infusion plus TACE with TACE alone for the treatment of HCC invading the hepatic vein, and found that cisplatin infusion significantly prolonged survival without increasing the incidence of adverse events. These results suggest that DDP-H may play a leading role in chemotherapy for HCC in the future. Anticancer agents are commonly used for the treatment of advanced HCC, but are rarely used for early-stage HCC because they result in reduction of the residual liver function. However, Overall survival in patients who received HAI with DDP-H before local treatment (HAI with DDP-H) and patients who did not receive HAI chemotherapy (non-HAI). There was a significant difference between the two groups (log-rank test, P = 0.023; generalized Wilcoxon test, P = 0.012). [7, 8] . Based on the results of our previous study, we proposed a treatment strategy consisting of whole-liver HAI with DDP-H before TACE/RFA to all patients with early-stage HCC that was appropriate for radical local treatment. However, some patients did not consent to HAI with DDP-H because this was not the standard therapy, and these patients were used as the controls (the non-HAI group) in the current study. To evaluate the effectiveness of DDP-H treatment, the patients who received HAI with DDP-H were compared with those who did not receive HAI chemotherapy. We previously compared the demographic and clinical characteristics of patients who consented to HAI with DDP-H and those who did not, and did not find any significant differences in tumor status or residual liver function between these two groups. The current study shows that survival time was significantly prolonged in JIS 0/1 HCC patients who received HAI with DDP-H compared with those who did not receive HAI chemotherapy. Multivariate analysis found that HAI with DDP-H was an independent predictor of survival. The factors associated with death were Child-Pugh class B liver function (HAI group: 0/7 patients; non-HAI group: 4/7 patients), multiple tumors (3/18, 3/3), tumor diameter >20 mm (2/23, 1/11), HCV infection (7/50, 7/18), and liver cirrhosis (6/40, 8/17) . Even in patients with more advanced liver disease, the mortality rate tended to be lower in the HAI group than in the non-HAI group, indicating that HAI with DDP-H was effective for the treatment of JIS 0/1 HCC. We speculate that previous studies [3] [4] [5] [6] did not show clinical benefits after neoadjuvant TACE/TAE with anticancer agents and lipiodol because the intrahepatic micrometastases that were not detected on imaging examinations were not treated. Based on our hypothesis, we prepared an aqueous solution with a high concentration of cisplatin and administered it to the whole liver via the proper hepatic artery. This strategy for the treatment of micrometastases resulted in prolonged survival compared with the results of previous studies of neoadjuvant TACE/TAE. The higher rate of adverse events in the HAI group can be attributed to the addition of adverse events caused by DDP-H to the adverse events caused by local treatment, and is consistent with the results of a monotherapy study of DDP-H that reported grade 3 or 4 thrombocytopenia in 25% of patients and an elevated AST level in 32.5% of patients [15] . The adverse events in the current study were transient and all resolved within 1 month. In Japan, surveillance via screening for early HCC among patients with chronic hepatitis has been conducted for years. This study assessed patients with chronic hepatitis who were screened for early HCC and diagnosed with JIS 0/1 HCC. They had relatively good liver function, sometimes associated with cirrhosis (HAI group: 51%; non-HAI group: 49%). These factors may have affected the tolerability of HAI. These findings suggest that long-term effects of DDP-H on liver function are clinically manageable for early-stage HCC (JIS 0/1).
The results of this study show that HAI with DDP-H before TACE and RFA/PEI for early-stage HCC (JIS 0/1) can prolong the time to recurrence after radical local treatment. This treatment can contribute to prolonging the survival time without causing liver or kidney dysfunction. Further prospective, multicenter trials are required to establish the usefulness of HAI with DDP-H for the treatment of HCC. In addition, it is necessary to determine whether whole-liver HAI with DDP-H is more beneficial as neoadjuvant or adjuvant therapy.
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